121 related articles for article (PubMed ID: 37013432)
1. Alpha Calcitonin Gene-related Peptide, Neuropeptide Y, and Substance P as Biomarkers for Diagnosis and Disease Activity and Severity in Multiple Sclerosis.
Al-Keilani MS; Almomani BA; Jaradat SA; Al-Sawalha NA; Qawasmeh MA
CNS Neurol Disord Drug Targets; 2024; 23(4):512-524. PubMed ID: 37013432
[TBL] [Abstract][Full Text] [Related]
2. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
3. Association study of two functional single nucleotide polymorphisms of neuropeptide y gene with multiple sclerosis.
Mohammadi SM; Shirvani Farsani Z; Dosti R; Sahraian MA; Behmanesh M
Neuropeptides; 2016 Dec; 60():45-50. PubMed ID: 27559040
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
Lanzillo R; Di Somma C; Quarantelli M; Ventrella G; Gasperi M; Prinster A; Vacca G; Pivonello C; Orefice G; Colao A; Morra VB
Eur J Neurol; 2011 Dec; 18(12):1402-6. PubMed ID: 21585623
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
6. Increased serum levels of some inflammatory markers in patients with multiple sclerosis.
Uysal S; Meriç Yilmaz F; Boğdaycioğlu N; Mungan Öztürk S; Ak F
Minerva Med; 2014 Jun; 105(3):229-35. PubMed ID: 24988088
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of neurogenic inflammation related neuropeptides in pediatric patients with community-acquired pneumonia and their potential diagnostic value in distinguishing viral and bacterial pneumonia.
Bekdas M; Saygi B; Kilinc YB; Kilinc E
Eur J Pediatr; 2024 Apr; 183(4):1619-1627. PubMed ID: 38183438
[TBL] [Abstract][Full Text] [Related]
8. Serum Levels of Biomarkers of Immune Activation and Associations With Neurological Impairment in Relapsing-Remitting Multiple Sclerosis Patients During Remission.
Witkowska AM; Socha K; Kochanowicz J; Karpińska E; Jakoniuk M; Zujko ME; Wilkiel M; Borawska MH; Mariak Z
Biol Res Nurs; 2016 Jan; 18(1):113-9. PubMed ID: 25911236
[TBL] [Abstract][Full Text] [Related]
9. Patterns of neuronal colocalisation of tyrosine hydroxylase, neuropeptide Y, vasoactive intestinal polypeptide, calcitonin gene-related peptide and substance P in human ureter.
Edyvane KA; Smet PJ; Trussell DC; Jonavicius J; Marshall VR
J Auton Nerv Syst; 1994 Aug; 48(3):241-55. PubMed ID: 7525686
[TBL] [Abstract][Full Text] [Related]
10. Chitinase-3-like 1-protein in CSF: a novel biomarker for progression in patients with multiple sclerosis.
Talaat F; Abdelatty S; Ragaie C; Dahshan A
Neurol Sci; 2023 Sep; 44(9):3243-3252. PubMed ID: 36988727
[TBL] [Abstract][Full Text] [Related]
11. Plasma concentration of selected neuropeptides in patients suffering from psoriasis.
Reich A; Orda A; Wiśnicka B; Szepietowski JC
Exp Dermatol; 2007 May; 16(5):421-8. PubMed ID: 17437485
[TBL] [Abstract][Full Text] [Related]
12. Significance of serum VIP and PACAP in multiple sclerosis: an exploratory case-control study.
Al-Keilani MS; Almomani BA; Al-Sawalha NA; Al Qawasmeh M; Jaradat SA
Neurol Sci; 2022 Apr; 43(4):2621-2630. PubMed ID: 34698942
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
[TBL] [Abstract][Full Text] [Related]
14. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.
Dickens AM; Larkin JR; Griffin JL; Cavey A; Matthews L; Turner MR; Wilcock GK; Davis BG; Claridge TD; Palace J; Anthony DC; Sibson NR
Neurology; 2014 Oct; 83(17):1492-9. PubMed ID: 25253748
[TBL] [Abstract][Full Text] [Related]
15. Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing-Remitting-Multiple Sclerosis Patients.
D'Angelo C; Reale M; Costantini E; Di Nicola M; Porfilio I; de Andrés C; Fernández-Paredes L; Sánchez-Ramón S; Pasquali L
Front Immunol; 2018; 9():1240. PubMed ID: 29915590
[TBL] [Abstract][Full Text] [Related]
16. Serum NSE level and disability progression in multiple sclerosis.
Koch MW; George S; Wall W; Wee Yong V; Metz LM
J Neurol Sci; 2015 Mar; 350(1-2):46-50. PubMed ID: 25686504
[TBL] [Abstract][Full Text] [Related]
17. Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis.
Whitaker JN; Wolinsky JS; Narayana PA; Bartolucci AA; Noseworthy JH; Lublin FD; Linde A; Gjörstrup P; Sullivan HC;
Arch Neurol; 2001 Jan; 58(1):49-54. PubMed ID: 11176936
[TBL] [Abstract][Full Text] [Related]
18. Lower Serum Zinc Levels in Patients with Multiple Sclerosis Compared to Healthy Controls.
Pawlitzki M; Uebelhör J; Sweeney-Reed CM; Stephanik H; Hoffmann J; Lux A; Reinhold D
Nutrients; 2018 Jul; 10(8):. PubMed ID: 30049983
[TBL] [Abstract][Full Text] [Related]
19. Serum Phosphorylated Neurofilament Heavy Chain Level in Relapsing Remitting Multiple Sclerosis in Correlation to Disease Activity and Disability.
Shehab AA; Solima DA; Abdel-Hafeez MA; Mohamed SM
Egypt J Immunol; 2019 Jan; 26(1):1-13. PubMed ID: 31332992
[TBL] [Abstract][Full Text] [Related]
20. Postmenopausal osteoporosis is associated with the regulation of SP, CGRP, VIP, and NPY.
Liu X; Liu H; Xiong Y; Yang L; Wang C; Zhang R; Zhu X
Biomed Pharmacother; 2018 Aug; 104():742-750. PubMed ID: 29807224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
